Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice

Masaru Kimata, Yoshihide Otani, Tetsuro Kubota, Naoki Igarashi, Takeyoshi Yokoyama, Norihito Wada, Nobunari Yoshimizu, Masato Fujii, Kaori Kameyama, Yasunori Okada, Koichiro Kumai, Masaki Kitajima

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Marimastat, a matrix metalloproteinese inhibitor, was examined for the ability to prevent peritoneal dissemination of a human gastric cancer xenograft, TMK-1. Even with novel approaches such as molecular targeting of cancer chemotherapy, peritoneal dissemination of gastric cancer has little sensitivity to anticancer drugs, and it is impossible to inhibit its growth completely. Intraperitoneal injection of TMK-1 into nude mice at 5 × 105 cells/body resulted in carcinomatous peritonitis that mimicked clinical cases. Continuous administration of marimastat (18 mg/kg/day) from 24 h after the tumor inoculation successfully inhibited the growth of peritoneal dissemination nodules. Combined administration of marimastat (18 mg/kg/day) and mitomycin C (MMC, 2 mg/kg) showed synergistic inhibition of growth of peritoneal dissemination, being superior to MMC alone (2 mg/kg). Although marimastat alone could not increase survival time with statistical significance, combined administration of marimastat and MMC had a survival benefit with statistical significance. The combination of marimastat and MMC increased the preventive effect on peritoneal dissemination. Marimastat seems to be a candidate for the prevention of peritoneal spread of gastric carcinoma.

Original languageEnglish
Pages (from-to)834-841
Number of pages8
JournalJapanese Journal of Cancer Research
Volume93
Issue number7
Publication statusPublished - 2002

Fingerprint

Matrix Metalloproteinase Inhibitors
Nude Mice
Stomach
Carcinoma
Stomach Neoplasms
Growth
Neoplasms
Survival
Mitomycin
marimastat
Intraperitoneal Injections
Peritonitis
Heterografts
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Gastric cancer
  • Marimastat
  • MMP inhibitor
  • Peritoneal dissemination

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kimata, M., Otani, Y., Kubota, T., Igarashi, N., Yokoyama, T., Wada, N., ... Kitajima, M. (2002). Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice. Japanese Journal of Cancer Research, 93(7), 834-841.

Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice. / Kimata, Masaru; Otani, Yoshihide; Kubota, Tetsuro; Igarashi, Naoki; Yokoyama, Takeyoshi; Wada, Norihito; Yoshimizu, Nobunari; Fujii, Masato; Kameyama, Kaori; Okada, Yasunori; Kumai, Koichiro; Kitajima, Masaki.

In: Japanese Journal of Cancer Research, Vol. 93, No. 7, 2002, p. 834-841.

Research output: Contribution to journalArticle

Kimata, M, Otani, Y, Kubota, T, Igarashi, N, Yokoyama, T, Wada, N, Yoshimizu, N, Fujii, M, Kameyama, K, Okada, Y, Kumai, K & Kitajima, M 2002, 'Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice', Japanese Journal of Cancer Research, vol. 93, no. 7, pp. 834-841.
Kimata, Masaru ; Otani, Yoshihide ; Kubota, Tetsuro ; Igarashi, Naoki ; Yokoyama, Takeyoshi ; Wada, Norihito ; Yoshimizu, Nobunari ; Fujii, Masato ; Kameyama, Kaori ; Okada, Yasunori ; Kumai, Koichiro ; Kitajima, Masaki. / Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice. In: Japanese Journal of Cancer Research. 2002 ; Vol. 93, No. 7. pp. 834-841.
@article{cc2d0c5bae8e4a9f847d945873a95c89,
title = "Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice",
abstract = "Marimastat, a matrix metalloproteinese inhibitor, was examined for the ability to prevent peritoneal dissemination of a human gastric cancer xenograft, TMK-1. Even with novel approaches such as molecular targeting of cancer chemotherapy, peritoneal dissemination of gastric cancer has little sensitivity to anticancer drugs, and it is impossible to inhibit its growth completely. Intraperitoneal injection of TMK-1 into nude mice at 5 × 105 cells/body resulted in carcinomatous peritonitis that mimicked clinical cases. Continuous administration of marimastat (18 mg/kg/day) from 24 h after the tumor inoculation successfully inhibited the growth of peritoneal dissemination nodules. Combined administration of marimastat (18 mg/kg/day) and mitomycin C (MMC, 2 mg/kg) showed synergistic inhibition of growth of peritoneal dissemination, being superior to MMC alone (2 mg/kg). Although marimastat alone could not increase survival time with statistical significance, combined administration of marimastat and MMC had a survival benefit with statistical significance. The combination of marimastat and MMC increased the preventive effect on peritoneal dissemination. Marimastat seems to be a candidate for the prevention of peritoneal spread of gastric carcinoma.",
keywords = "Gastric cancer, Marimastat, MMP inhibitor, Peritoneal dissemination",
author = "Masaru Kimata and Yoshihide Otani and Tetsuro Kubota and Naoki Igarashi and Takeyoshi Yokoyama and Norihito Wada and Nobunari Yoshimizu and Masato Fujii and Kaori Kameyama and Yasunori Okada and Koichiro Kumai and Masaki Kitajima",
year = "2002",
language = "English",
volume = "93",
pages = "834--841",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice

AU - Kimata, Masaru

AU - Otani, Yoshihide

AU - Kubota, Tetsuro

AU - Igarashi, Naoki

AU - Yokoyama, Takeyoshi

AU - Wada, Norihito

AU - Yoshimizu, Nobunari

AU - Fujii, Masato

AU - Kameyama, Kaori

AU - Okada, Yasunori

AU - Kumai, Koichiro

AU - Kitajima, Masaki

PY - 2002

Y1 - 2002

N2 - Marimastat, a matrix metalloproteinese inhibitor, was examined for the ability to prevent peritoneal dissemination of a human gastric cancer xenograft, TMK-1. Even with novel approaches such as molecular targeting of cancer chemotherapy, peritoneal dissemination of gastric cancer has little sensitivity to anticancer drugs, and it is impossible to inhibit its growth completely. Intraperitoneal injection of TMK-1 into nude mice at 5 × 105 cells/body resulted in carcinomatous peritonitis that mimicked clinical cases. Continuous administration of marimastat (18 mg/kg/day) from 24 h after the tumor inoculation successfully inhibited the growth of peritoneal dissemination nodules. Combined administration of marimastat (18 mg/kg/day) and mitomycin C (MMC, 2 mg/kg) showed synergistic inhibition of growth of peritoneal dissemination, being superior to MMC alone (2 mg/kg). Although marimastat alone could not increase survival time with statistical significance, combined administration of marimastat and MMC had a survival benefit with statistical significance. The combination of marimastat and MMC increased the preventive effect on peritoneal dissemination. Marimastat seems to be a candidate for the prevention of peritoneal spread of gastric carcinoma.

AB - Marimastat, a matrix metalloproteinese inhibitor, was examined for the ability to prevent peritoneal dissemination of a human gastric cancer xenograft, TMK-1. Even with novel approaches such as molecular targeting of cancer chemotherapy, peritoneal dissemination of gastric cancer has little sensitivity to anticancer drugs, and it is impossible to inhibit its growth completely. Intraperitoneal injection of TMK-1 into nude mice at 5 × 105 cells/body resulted in carcinomatous peritonitis that mimicked clinical cases. Continuous administration of marimastat (18 mg/kg/day) from 24 h after the tumor inoculation successfully inhibited the growth of peritoneal dissemination nodules. Combined administration of marimastat (18 mg/kg/day) and mitomycin C (MMC, 2 mg/kg) showed synergistic inhibition of growth of peritoneal dissemination, being superior to MMC alone (2 mg/kg). Although marimastat alone could not increase survival time with statistical significance, combined administration of marimastat and MMC had a survival benefit with statistical significance. The combination of marimastat and MMC increased the preventive effect on peritoneal dissemination. Marimastat seems to be a candidate for the prevention of peritoneal spread of gastric carcinoma.

KW - Gastric cancer

KW - Marimastat

KW - MMP inhibitor

KW - Peritoneal dissemination

UR - http://www.scopus.com/inward/record.url?scp=0036048505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036048505&partnerID=8YFLogxK

M3 - Article

C2 - 12149150

AN - SCOPUS:0036048505

VL - 93

SP - 834

EP - 841

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 7

ER -